Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN).

Full DD Report for ALXN

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALXN)

JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size ...
Source: SeekingAlpha
Date: May, 14 2018 11:37
Institutional Top Ideas Series: Ra Capital Management
In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su...
Source: SeekingAlpha
Date: May, 10 2018 02:04
Alexion to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Wednesday, May 16, 2018 at 2:20 p.m., PDT. An audio webcast of the presentation will be available live. You can access the webca...
Source: Business Wire
Date: May, 08 2018 16:30
JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space
Welcome to the fourteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size...
Source: SeekingAlpha
Date: May, 07 2018 15:40
Daily Insider Ratings Round Up 5/2/18: SOHU, BW, DDR, NHF, ABCP, ALXN
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: May, 05 2018 14:36
Institutional Top Ideas Series: Orbimed Advisors
In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of...
Source: SeekingAlpha
Date: May, 04 2018 03:18
How To Play 'Am I Diversified?' In The Pharma/Biotech Space
Background Many investors (including myself) regularly watch or listen to the show "Mad Money" by Jim Cramer on CNBC. As with any celebrity, Mr. Cramer tends to be polarizing, with some loving him and some reveling in pointing out when he is wrong. Rather than focusing on his individual stoc...
Source: SeekingAlpha
Date: May, 03 2018 00:54
JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond
Welcome to the thirteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size...
Source: SeekingAlpha
Date: May, 01 2018 02:41
Alexion Clears A Path For 2nd Generation PNH Drug
Recently, Alexion Pharmaceuticals ( ALXN ) announced positive results from another phase 3 study for its second generation version of Soliris, known as ALXN1210. This study is good news for the company, because the trial showed that patients can be switched from soliris to ALXN1210 witho...
Source: SeekingAlpha
Date: April, 30 2018 04:36
3 Things In Biotech, April 27: AbbVie And Alexion Move Forward, ADC Moves Back
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a...
Source: SeekingAlpha
Date: April, 28 2018 08:01

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-17120.86121.15121.98119.69755,982
2017-06-20117.00119.05120.79116.663,592,187
2017-06-19114.51116.16117.075113.222,694,095
2017-06-16118.02113.98118.55113.134,622,346
2017-06-15116.50117.98118.03115.946,260,916

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1746,203174,20726.5219Cover
2018-08-1692,717356,21826.0282Cover
2018-08-15172,224473,65336.3608Short
2018-08-1468,033197,80234.3945Cover
2018-08-1361,417278,93822.0182Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALXN.


About Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)

Logo for Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)

Not available

 

Contact Information

 

 

Current Management

  • Leonard Bell / President, CEO, Secretary
  • David W. Keiser / COO

Current Share Structure

  • Market Cap: $27,334,206,450 - 05/14/2018
  • Issue and Outstanding: 222,500,663 - 04/23/2018

 


Recent Filings from (NASDAQ: ALXN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 11 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 28 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 28 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 12 2018

 

 


Daily Technical Chart for (NASDAQ: ALXN)

Daily Technical Chart for (NASDAQ: ALXN)


Stay tuned for daily updates and more on (NASDAQ: ALXN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ALXN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALXN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ALXN and does not buy, sell, or trade any shares of ALXN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/